 |
PFE
http://bit.ly/93O06I $PFE Drugmakers Pfizer, Roche Disappoint With Forecasts
PFE
http://bit.ly/c4azSL $PFE Pfizer Misses Estimates, and Shares Slide
PFE
$pfe : Katsenelson likes the company.perfect stock for this economy.http://bit.ly/9pX5Uv #stocks
PFE
$PFE Like California's state govt, it has become place to stash political hacks & retreads in between elections. http://bit.ly/dxvQeT
PFE
Pfizer Inc $PFE Somewhat Down. Allens acts for Pfizer on divestment of animal health assets: http://bit.ly/d9eVLw
PFE
Pfizer Inc $PFE Somewhat Down. Chartpoppers.com releases Investment Analysis on Bristol Mye: http://bit.ly/aKk9Jz
PFE
Pfizer Inc $PFE Somewhat Down. BRIEF: Bristol-Myers freezing salaries: http://bit.ly/8X4WDG
PFE
Pfizer Inc $PFE Somewhat Down. BRIEF: Bristol-Myers freezing salaries: http://bit.ly/92Invt
PFE
$PFE, sell / short @ market,1st target $16.92, use a stop close only order above $19.26; Selling March $20 calls also warranted.
PFE
@drpdtapp $DNA's Avastin was also approved in renal cancer. All on top of $PFE's Sutent, Torisel and $ONY Nexavar
PFE
$PFE seeing lots of shares trading. http://tinyurl.com/ykw6x86
PFE
$PFE RT @ChristianeTrue @MattD19: Kindler took chance & stood on 1 side of aisle.Unfortunately,may not pay off Via @WSJ http://bit.ly/bC
PFE
RT @reutersBenHir: Will cutting research kill or cure Big Pharma? http://tinyurl.com/yc4kee8 $GSK $AZN $PFE
PFE
Will cutting research kill or cure Big Pharma? http://tinyurl.com/yc4kee8 $GSK $AZN $PFE
PFE
Trust evaporates after Pfizer's Q4 erns. RT @Jim_Edwards Wall Street furious about $PFE's numbers games. http://bit.ly/9LRDsm
PFE
Pfizer Inc $PFE Not Moving. MARKET WATCH: Global stocks close sideways on investor cauti: http://bit.ly/aQ1Tkq
PFE
Pfizer Inc $PFE Not Moving. MARKET WATCH: Global stocks close sideways on investor cauti: http://bit.ly/96eLsr
PFE
Pfizer Inc $PFE Moderately Down, Lost over 3%. Drug adopted by Pfizer OK'd: Xiaflex treats progressive: http://bit.ly/aBXhr8
PFE
spreads, but smaller does not so much. Possible to arbitrage $64B $WYE/$PFE transaction for abt 40% annualizd rates return. $SGP/$MRK was
PFE
RT @MaverickNY - RT @mhuckman: On an ugly day for the stock market Dow components Pfizer $PFE finished down 3%, Merck $MRK off 4% & J&am
PFE
RT @mhuckman: On an ugly day for the stock market Dow components Pfizer $PFE finished down 3%, Merck $MRK off 4% & J&J $JNJ -1.5%.
PFE
Berkowitz on Pharma (shifting from D to O) $PFE http://bit.ly/cBQw88
PFE
Pos dvlpmnt for nwly diag GBM patients - RT @ChristianeTrue @mhuckman $PFE $QGEN to develop EGFRvIII companion test 4 $CLDX/$PFE vaccine
PFE
RT @mhuckman: Pfizer & Qiagen $PFE $QGEN hook up on brain cancer diagnostic to see who might respond to experimental Celldex/PFE tmt. $C
PFE
On an ugly day for the stock market Dow components Pfizer $PFE finished down 3%, Merck $MRK off 4% & J&J $JNJ -1.5%.
PFE
RT @mhuckman: Pfizer & Qiagen $PFE $QGEN hook up on brain cancer diagnostic to see who might respond to experimental Celldex/PFE tmt. $C
Pfizer Inc. - PFE Insiders
pfizer, 1658 follower(s), 473 friend(s)Pfizer Inc. - PFE information
Pfizer Inc. engages in the discovery, development, manufacture, and marketing of prescription medicines for humans and animals worldwide. Its Pharmaceutical segment offers Lipitor for elevated cholesterol levels in the blood; Norvasc for hypertension; Caduet for cardiovascular events; Chantix/Champix for smoking cessation; Lyrica for neuropathic pain; Geodon/Zeldox, a psychotropic agent; and Aricept for Alzheimer?s disease. It also provides Celebrex for arthritis pain, and inflammation and acute pain; Vfend for esophageal candidiasis and blood stream infections; Zyvox for bacterial infections; and Selzentry/Celsentri for adults infected with only CCR5-tropic HIV-1 detectable. In addition, this segment provides Viagra for erectile dysfunction; Detrol and Toviaz for overactive bladder; Camptosar for metastatic colorectal cancer; Sutent, an oral multi-kinase inhibitor; Xalatan/Xalacom for open-angle glaucoma and ocular hypertension; and Genotropin for growth disorders. The company?s Animal Health segment offers parasiticides, anti-inflammatories, antibiotics, vaccines, antiemetics, and anti-obesity agents. It also provides Revolution/Stronghold for dogs and cats; Rimadyl for pain and inflammation associated with canine osteoarthritis and soft tissue orthopedic surgery; Clavamox/Synulox for skin and soft tissue infections; RespiSureOne/StellamuneOne to prevent pneumonia in swine; Bovi-Shield Gold for reproductive and respiratory protection; Dectomax, an injectable and pour-on formulations; Draxxin, an antibiotic for infections in cattle and swine; and Excede to treat infections in dairy cows, beef cattle, and swine. Pfizer Inc. also involves in contract manufacturing and bulk pharmaceutical chemicals businesses. It serves doctors, nurse practitioners, physician assistants, pharmacists, hospitals, pharmacy benefit managers, managed care organizations, and government agencies. The company was founded in 1849 and is headquartered in New York, New York....
www.pfizer.com
Founded in 1849
PFIZER INC (PFE:NYSE)
LAST $17.22 USD
CHANGE TODAY -0.13 -0.75%
VOLUME 3.4M
As of 9:47 AM 03/9/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of PFIZER INC (PFE)
|
OPEN
$17.27
|
PREVIOUS CLOSE
$17.48
|
|
|
DAY HIGH
$17.32
|
DAY LOW
$17.21
|
|
|
52 WEEK HIGH
01/20/10 - $20.36
|
52 WEEK LOW
03/9/09 - $12.38
|
|
|
MARKET CAP
139.1B
|
AVERAGE VOLUME 10 D
61.8M
|
|
|
EPS TTM
$2.03
|
SHARES OUTSTANDING
8.1B
|
|
|
EX-DATE
02/3/10
|
P/E TTM
8.5x
|
|
|
DIVIDEND
$0.72
|
DIVIDEND YIELD
3.80%
|
|
| K = Thousands M = Millions B = Billions | ||
related news
*Merck, Sanofi combining animal medicine businesses
AP Digital - 03/09/2010 2:00 AM ET
Final Glance: Pharmaceuticals companies
AP Digital - 03/08/2010 5:50 PM ET
Midday Glance: Pharmaceuticals companies
AP Digital - 03/08/2010 4:40 PM ET
Court to rule in military funeral protest case
AP Digital - 03/08/2010 3:42 PM ET
Court will hear case about vaccine side effects
AP Digital - 03/08/2010 10:55 AM ET
Key developments for PFIZER INC (PFE)
Pfizer Inc. Announces Executive Changes
02/25/2010
Pfizer Inc. announced that William Ringo will retire from the company as Senior Vice President, Worldwide Business Development, Strategy and Innovation. Mr. Ringo made many important contributions to advance the company's innovative business development activities. Mr. Ringo joined Pfizer in April 2008, after retiring from Eli Lilly & Company, where over his 28-year tenure he held a number of senior positions. Between working for Lilly and Pfizer he served in leadership roles for both venture capital and biotechnology companies. Mr. Ringo, whose retirement will be effective April 30, 2010, will help his successor during a transition period. Kristin Peck, who will succeed Mr. Ringo, has been named Senior Vice President of Worldwide Business Development, Strategy and Innovation. Most recently, she played a leadership role in the integration of Wyeth's global operations, while serving as Senior Vice President of Worldwide Strategy and Innovation. Working closely with the business leadership, Ms. Peck will assume responsibility for business development activities, ensuring their alignment with Pfizer's strategic objectives. She will report directly to Mr. Kindler and join Pfizer's Executive Leadership Team. Ms. Peck joined Pfizer in 2004 in the company's strategic planning organization. Prior to Pfizer, she was a principal with the Boston Consulting Group and worked in real estate financial services and private equity at Prudential and The O'Connor Group.
Pfizer Inc. Presents at 4th Annual Global Clinical Trial Partnerships: Optimizing Cross-Border Outsourcing Conference, Mar-01-2010
02/25/2010
Pfizer Inc. Presents at 4th Annual Global Clinical Trial Partnerships: Optimizing Cross-Border Outsourcing Conference, Mar-01-2010. Venue: HYATT REGENCY PRINCETON, PRINCETON, New Jersey, United States. Speakers: Dianne Kikta, Vice President Global Clinical Strategic Resourcing.
Pfizer Inc. Presents at Drug Development Latin America: Effectively Planning and Implementing Clinical Research and Trials, Mar-10-2010
02/25/2010
Pfizer Inc. Presents at Drug Development Latin America: Effectively Planning and Implementing Clinical Research and Trials, Mar-10-2010. Venue: Crowne Plaza Philadelphia Downtown, 1800 Market Street, Philadelphia, PA 19103, United States. Speakers: Ana Maria Valderrama, Area Head, Clinical Operations, Canada/Latin America/Africa/Middle East Region.
PFE Competitors
| Company | Last | Change |
| Bayer AG | €51.98 EUR | +0.25 |
| Kraft Foods Inc | $29.35 USD | +0.18 |
| Novartis AG | SFr.58.85 CHF | +0.40 |
| Roche Holding AG | SFr.181.40 CHF | +0.90 |
| Sanofi-Aventis SA | €56.13 EUR | +0.38 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | PFE | Industry Range |
| Price/Earnings | 14.2x |
|
| Price/Sales | 2.7x |
|
| Price/Book | 1.6x |
|
| Price/Cash Flow | 12.2x |
|
| TEV/Sales | 1.3x |
|
|
PFE |
||
|
PFE transactions
| Type Date |
Target |
|
Private Placement
January 29, 2010 |
Merus B.V. |
|
Merger/Acquisition
January 12, 2010 |
Pfizer Inc., Certain Veterinary Products and Related Assets |
|
Merger/Acquisition
December 21, 2009 |
Durata Therapeutics, Inc. |
Pfizer Inc. - PFE news
UPDATE - US court to decide if vaccine makers can be sued
2010-03-09 01:23:30
Keywords: Pharmaceuticals (sub-industry),Biotechnology,United States of America,Health and medicine,Washington / US Government News,Legislation,Judicial processes/court cases/court decisions,Pharmaceuticals - diversified,Healthcare,Israel,Middle East,Domestic Polit
Quote: UPDATE 2-US court to decide if vaccine makers can be sued
* Case involves Wyeth, which Pfizer purchased last year * Child developed seizures after third dose of DTP vaccine * Supreme Court to hear arguments in upcoming term * Pfizer shares fall 1 percent(Adds Pfizer comments, shares)James Vicini WASHINGTON, March 8 (Reuters) - The U.S. Supreme Court said
on Monday that it would decide whether a federal law protects
vaccine manufacturers from lawsuits in state court seeking
damages for alleged d...Read article
Court will hear case about vaccine side effects
2010-03-09 01:23:30
Quote: Circuit Court of Appeals in Philadelphia ruled against Robalee and Russell Bruesewitz, saying a 1986 federal law bars their claims.That law set up a special vaccine court to handle disputes as part of its aim of insuring a stable vaccine supply by shielding companies from most lawsuits.Wyeth, now owned by Pfizer, Inc., prevailed at the appeals court but also joined in asking the court to hear the case, saying it presents an important and recurring legal issue that should be resolved.The Obama ad...Read article
Q&A-Leerink Swann on expected U.S. health reform
2010-03-09 01:23:29
Keywords: United States of America,Equities,Health and medicine,Pharmaceuticals (sub-industry),Mergers and Acquisitions (including Changes of Ownership),Washington / US Government News,Pharmaceuticals - diversified,General News,Nature Society and Science,Business a
Quote: There are some significant products coming generic over the
next couple of years, (Pfizer's (PFE.N) cholesterol drug)
Lipitor being the biggest. The big risk is it's not as big a
benefit for the generics industry as investors currently
anticipate. I'm not recommending the generics subsector today
because I think all this anticipation is already contained in
the value of the stocks. Similarly, I'm not really recommending distributors right
now, because they benefit like generics do. Q-What would ...Read article
Actavis plays IPO card in Ratiopharm battle-sources
2010-03-09 01:23:28
Keywords: Germany,Western Europe,Europe,Iceland,Nordic Countries,Israel,Middle East,United States of America,Pharmaceuticals - generic and speciality,Pharmaceuticals (sub-industry),Health and medicine,Mergers and Acquisitions (including Changes of Ownership),Banks
Quote: Executives at Actavis, which is vying with with Pfizer
(PFE.N) and Teva (TEVA.TA), said in a presentation to
Ratiopharm's top management that an initial public offering
could be carried out in 5-8 years, the sources told Reuters. Actavis opted to forgo backing from Swedish buyout firm EQT
in the Ratiopharm auction, several sources told Reuters last
month. Deutsche Bank (DBKGn.DE), Actavis's main lender and which,
according to sources, is owed more than 4 billion euros ($5.5
billion), has approve...Read article
High Court Wades Into Funeral Protests, Vaccines
2010-03-09 01:23:26
Quote: WyethPfizer Inc. Wyeth denies that its vaccine caused the injuries.
The case is the latest in which the Supreme Court will decide whether federal laws pre-empt state regulation on medical matters.
The justices have found that a federal law pre-empts suits against medical-device manufacturers filed under state liability statutes, but different language applying to drugs permits similar claims against pharmaceutical companies.
The Third U.S. Circuit Court of Appeals in Philadelphia ruled last yea...Read article
Court to rule in military funeral protest case
2010-03-09 01:23:26
Quote: Now a teenager, Hannah suffers from residual seizure disorder, the suit says.The vaccine court earlier rejected the family's claims and Wyeth, now owned by Pfizer, Inc., prevailed in a federal appeals court ruling.Wyeth lost another high court fight last year over whether federal law barred lawsuits against drug makers. That case, involving a botched injection, asked whether federal law included an implicit prohibition on the lawsuits. The court said it did not.In this appeal, however, Congress ...Read article
UPDATE - Bristol-Myers post-Plavix view better than feared
2010-03-05 06:37:18
Keywords: Pharmaceuticals - diversified,Pharmaceuticals (sub-industry),United States of America,Corporate Results Forecasts,Corporate Results,Regulation and enforcement,France,Western Europe,Europe,Healthcare,Pharmaceuticals and biotechnology,Business activities,Co
Quote: recommendation this week; the blood-clot drug
apixaban being co-developed with Pfizer; diabetes medicine
dapagliflozin; liver cancer therapy brivanib; and ipilimumab. Bristol also gave an overview about its research progress
in Alzheimer's disease, for which it has drugs in early and
mid-stage development, and in hepatitis C, with medicines it
hopes can boost cure rates and shorten treatment durations. The company said it had 60 compounds in development, with
seven in late-stage trials or awaiti...Read article
A Ray Of Hope For Medivation
2010-03-05 06:37:18
Keywords: Medicine, Pharmacuticals, Health Care, Drugs, Drug Companies, Hospitals, Health Insurance
Quote: But the drug may not be completely dead yet, says University of Southern California Alzheimer's expert Lon Schneider.
Schneider, who generally has been skeptical of Dimebon (see this post), does point to one small ray of hope for Medivation and its partner Pfizer buried in yesterday's news release: It turned out that while Dimebon did nothing to improve the cognitive abilities of Alzheimer's patients (the primary goal of the trial), patients who took the drug did improve slightly over the c...Read article
ADVANCE-2 Study Results Demonstrate Investigational Anticoagulant Apixaban Was Statistically Superior To Enoxaparin In The Prevention Of Venous Thromboembolism Following Knee Replacement Surgery
2010-03-05 06:37:15
Quote: Bristol-MyersSquibb CompanyNYSEBMYNewsPfizerInc.NYSEPFENewsThe Lancet. Thestudy results also showed numerically lower rates of major andclinically relevant non-major bleeding in patients treated with apixabancompared with those treated with enoxaparin. These results did not meetstatistical significance.nd Congress of theInternational Society on Thrombosis and Haemostasis in Boston.Patients undergoing major orthopedic surgery, including total kneereplacement, are at high risk for venous thromboem...Read article
[$$] Alzheimer's Drug Falls Short
2010-03-04 05:31:59
Quote: WANGPfizer said Wednesday that a promising Alzheimer's drug failed to work in a pivotal study, marking a setback for the giant drug maker's efforts to revive its pipeline. Pfizer and partner Medivation Inc. said the experimental drug, Dimebon, failed to meet its primary and secondary goals—improving thinking ability and overall daily function over six months in patients with mild-to-moderate Alzheimer's disease. The multinational trial of 598 patients showed no significant benefit from th...Read article
[$$] Pfizer Readies Ratiopharm Bid
2010-03-04 05:31:58
Quote: BY WILLIAM LAUNDER AND EYK HENNINGPfizer Inc. plans to bid as much as $4 billion for German generic drug maker Ratiopharm Group International, according to people familiar with the matter, in an effort that would further diversify the New York drug giant. The offer would intensify the battle for Ratiopharm, which Israeli generic drug giant Teva Pharmaceutical Industries Ltd. and Iceland's Actavis Group are also said to be bidding for. Ratiopharm is one of the leading generic drug makers in Eur...Read article
Big Pharma Best Skip Course in Medivation
2010-03-04 05:31:58
Quote: PfizerMedivation fell flat in a late-stage trial. Shares of Medivation plunged 67%. Pfizer's fell 2%.
Pfizer investors might be tempted to shrug off the failure. After all, it cost the pharmaceutical company an initial $225 million to join the partnership in 2008. Pfizer's market capitalization is $140 billion. But what is troubling is how much Medivation was able to take advantage of a drug that was miles from being marketed. Dimebon, first developed decades ago as an antihistamine, had shown ...Read article
'Fast Money' Recap: Political Gridlock
2010-03-04 05:31:58
Keywords: Financial, News, Stock, Market, Headlines, Investments, Quotes, Trading, TheStreet.com, David Tong ,Fast Money Recap
Quote: Daniel Clifton, head of policy research for Strategas, said it's important that the Obama administration is sticking with its proposal, but he doubted whether there will be much teeth in the bill after it gets through Congress.He said much of the Volcker Plan won't go through but he added the bill could give the Fed the power to take away the ability for proprietary trading if it is worried about "systemic risk."Jon Najarian agreed with the assessment but he noted that the financials also face t...Read article
Bristol-Myers CEO to retire; COO to succeed him
2010-03-03 01:52:17
Quote: He previously worked for two other drug companies, KABI Pharmacia and then Pharmacia & Upjohn, which now is part of Pfizer Inc.Andreotti holds a bachelor's degree in engineering from the University of Rome, and a master's degree from the Massachusetts Institute of Technology.Cornelius will retire on May 4, 2010. He became Bristol's chairman in February 2008 after being elected CEO by the board of directors in April 2007. That was after Cornelius had served as interim CEO for about eight mont...Read article
PFIZER INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year
2010-03-03 01:52:17
Quote: Item 5.03Amendments to Articles of Incorporation or Bylaws; Change in Fiscal
Year.
On February 25, 2010, the Board of Directors of Pfizer Inc. (the "Company")
approved the amendment of Article III, Section 3, of the Company's By-laws.The
amendment eliminates the presumption that the role of Chairman be held by the
Chief Executive Officer and also clarifies the role of the Chairman with respect
to meetings of the Board of Directors.
The preceding is qualified in its entirety by refe...Read article
UPDATE - Pfizer to outline Ratiopharm offer this week-sources
2010-03-03 01:52:16
Keywords: Mergers and Acquisitions (including Changes of Ownership),Germany,Western Europe,Europe,Pharmaceuticals - diversified,Pharmaceuticals (sub-industry),United States of America,Emerging countries,Israel,Middle East,Business activities,Contract between 2 or m
Quote: UPDATE 1-Pfizer to outline Ratiopharm offer this week-sources
* Pfizer set to outline offer this week - sources * Teva and Actavis still in the running - sources (Recasts, changes sourcing, adds details) NEW YORK, March 2 (Reuters) - Pfizer Inc (PFE.N) is set to
present a nearly $4 billion offer for German generic-drug maker
Ratiopharm GmbH this week, competing against rival bids from Teva
Pharmaceutical Industries Ltd (TEVA.TA) and Actavis, sources
familiar with the situation said on Tuesday. ...Read article
Bristol's Accidental Revolutionary
2010-03-03 01:52:16
Keywords: Medicine, Pharmacuticals, Health Care, Drugs, Drug Companies, Hospitals, Health Insurance
Quote: Cornelius, a board member who served as chief executive of Guidant when it was bought by Boston Scientific, was widely expected to sell Bristol to Plavix partner Sanofi-Aventis or larger rival Pfizer. He discarded non-core businesses, selling the company’s wound-therapy business to private equity firms and spinning off Mead Johnson, a baby formula business. He was outbid for ImClone, Bristol’s partner on the cancer drug Erbitux, by Eli Lilly, but bought three other biotechs: Medarex,...Read article
Pfizer to outline Ratiopharm offer this week
2010-03-03 01:52:15
Quote: PFENewsTEVA.TANews) and Actavis, sources familiar with the situation said on Tuesday.Pfizer had previously cooled on Ratiopharm, but was asked to rejoin the auction and make a presentation to Ratiopharm's board and management, one source said.Pfizer was expected to "be competitive" with a rival offer from Iceland's Actavis, the source said. Pfizer could still walk away without submitting a binding offer, the source cautioned.The auction could linger several more weeks, with a decision unlikely b...Read article
Pfizer Going For Generic Crown: Report
2010-03-03 01:52:14
Keywords: Financial, News, Stock, Market, Headlines, Investments, Quotes, Trading, TheStreet.com, Eric Rosenbaum ,Drugs
Quote: Updated from Tuesday, March 2TheStreet) -- Drug giant PfizerPFE Quote), the world's biggest drug-maker, may be getting bigger. Pfizer is reportedly bidding more than $4 billion to acquire German generic drug firm Ratiopharm.Bloomberg on Tuesday afternoon, would be the biggest generic drug deal since Teva Pharmaceutical IndustriesTEVA Quote) bought Barr Pharmaceuticals in 2008 for $7.4 billion.Bloomberg report.Teva is not planning to allow Pfizer to match its generic drug-buying prowess so easily...Read article
Pfizer Said to Set Sights on German Drug Maker
2010-03-03 01:52:14
Keywords: Mergers & Acquisitions, Investment Banking, I PO, I.P.O.s, IPOs, Offerings, Private Equity, Hedge Funds, Venture Capital, Legal, The New York Times, Andrew Ross Sorkin, Andrew Sorkin, DealBook, deal maker, Wall street, wall st., Goldman Sachs, Goldman Sa
Quote: Pfizer is reportedly gearing up this week to bid 3 million euro ($4.08 billion) for Ratiopharmaccording to Bloomberg News, which cited two unidentified people with knowledge of the talks.The move would pit Pfizer, the world’s largest drug maker, against Teva Pharmaceuticals Industries of Israel, the world’s largest generic drug maker, and Actvis of Iceland, another big generic drug maker, both of which are said to be interested in Ratiopharm, according to Bloomberg.
The news comes ...Read article